Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.46 |
| ▸ | TK2 | O00142 | 10/20 | 0.46 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | SLC6A1 | P30531 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20032425 | 1.00 | KIF11 (0.55) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL8868959 | 0.98 | KIF11 (0.57) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL2489713 | 0.92 | KIF11 (0.59) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL18095444 | 0.90 | KIF11 (0.49) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL6849984 | 0.87 | SLC6A11 (0.46) | KIF11TK2SLC6A1CYP3A4KCNH2 | |
| SCHEMBL887485 | 0.87 | SLC6A11 (0.46) | KIF11TK2SLC6A1CYP3A4KCNH2 | |
| SCHEMBL27051202 | 0.87 | SLC6A11 (0.46) | KIF11TK2SLC6A1CYP3A4KCNH2 | |
| SCHEMBL1260569 | 0.87 | SLC6A11 (0.46) | KIF11TK2SLC6A1CYP3A4KCNH2 | |
| SCHEMBL13427508 | 0.87 | SLC6A11 (0.46) | KIF11TK2SLC6A1CYP3A4KCNH2 | |
| SCHEMBL4455872 | 0.87 | KIF11 (0.50) | KIF11HRH4TK2TK1DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023074936-A1 | BIFUNCTIONAL COMPOUND USING UBR BOX DOMAIN-BINDING LIGAND | 주식회사 오토텍바이오 | 2023-05-04 | — | — | WO | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-8017620-B2 | Dutpase inhibitors | MEDIVIR AB (SE) | 2011-09-13 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021459-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2011-01-27 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-7795270-B2 | DUTPase inhibitors | MEDIVIR AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080312183-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| US-20080300216-A1 | Dutpase Inhibitors | MEDIVIR AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1701952-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| EP-1701727-A1 | DUTPASE INHIBITORS | Medivir Aktiebolag (SE) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066160-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| WO-2005065689-A1 | DUTPASE INHIBITORS | MEDIVIR AB (SE) | 2005-07-21 | — | — | WO | disclosed |
| EP-1543019-A2 | MODIFIED PNA MOLECULES | Santaris Pharma A/S (DK) | 2005-06-22 | — | — | EP | disclosed |
| WO-2004024757-A2 | MODIFIED PNA MOLECULES | SANTARIS PHARMA A/S (DK) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300216-A1 | Dutpase Inhibitors | DUT, DHODH, POLR2H | KIF11 4014/4885HRH4 315/4885TK2 418/4885 |
| US-20080312183-A1 | Dutpase Inhibitors | DUT, DHODH, RNASEH1 | KIF11 2729/4885HRH4 169/4885TK2 224/4885 |
| US-20110021459-A1 | DUTPASE INHIBITORS | DUT, DHODH, NAT10 | KIF11 2686/4885HRH4 179/4885TK2 259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.